# White House Drug Strategy Targets Hemp Products While Trump Calls for CBD Protections
*The administration’s mixed signals on hemp leave the industry guessing which products survive the November deadline.*
**By CBDWorldNews Editorial Staff | May 10, 2026**
The White House released its 2026 National Drug Control Strategy on May 4, and hemp industry leaders are parsing every line for clues about what comes next.
The biennial report from the Office of National Drug Control Policy (ONDCP) outlines a “whole-of-government approach” to dismantle illicit drug supply chains. Among its targets: unregulated psychoactive derivatives of hemp, including delta-8 THC and other intoxicating cannabinoids that have flooded convenience stores and gas stations since the 2018 Farm Bill opened the door.
But the strategy arrives against a backdrop of contradictory signals from the same administration.
## The Enforcement Push
The drug control strategy frames certain hemp-derived products alongside fentanyl and illicit cannabis as threats requiring coordinated federal action. It calls for intensified prosecution of “the illicit production and distribution of dangerous substances,” specifically naming high-potency cannabis from criminal operations and unregulated psychoactive hemp derivatives.
For an industry that has operated in a regulatory gap for years, the language represents a formal escalation. Federal agencies now have a strategic document they can point to when justifying enforcement actions against hemp-derived intoxicants.
The strategy also signals increased collaboration between the DEA, FDA, and state regulators. That coordination could accelerate the patchwork of state-level crackdowns already underway in Texas, where smokeable hemp was [pulled from shelves again this week](https://cbdworldnews.com/2026/05/10/texas-hemp-appeal), and in other states tightening rules ahead of the November federal deadline.
## Trump’s CBD Carve-Out
Here is where the picture gets complicated. President Trump called on Congress last month to revise the language of the forthcoming hemp product ban to ensure “Americans can continue to access the full-spectrum CBD products they have come to rely on.”
That statement drew a clear line: intoxicating hemp products face a crackdown, but traditional CBD — the non-intoxicating cannabinoid used in oils, topicals, and wellness products — should remain available.
The problem is that the current federal redefinition does not make that distinction cleanly. By switching to a total THC standard that counts THCA, the new definition catches full-spectrum CBD products in the same net as delta-8 gummies and THC seltzers.
> “The president wants to protect CBD, but the law he signed doesn’t do that. Someone has to fix the language before November.”
Industry advocates say Trump’s statement created political cover for a legislative fix, but Congress has not acted on it. The 2026 Farm Bill passed the House on April 30 without any delay to the November ban or any specific CBD protection language.
## What This Means for CBD Companies
Companies selling [full-spectrum CBD products](https://cbdproducts.com/buying-guides/full-spectrum-cbd-oil) face a narrowing window. The drug control strategy signals enforcement intent. Trump’s statement signals political sympathy. Neither translates into regulatory clarity.
The practical question for CBD manufacturers: do you reformulate now to meet the total THC standard, or do you bet on Congress passing a fix before November 12?
Reformulation carries real costs. Removing THCA from full-spectrum products changes their cannabinoid profile and, according to many users, reduces their effectiveness. Broad-spectrum and isolate products avoid the THC issue entirely but command lower prices and different customer loyalty.
Several major CBD brands have already begun offering both full-spectrum and THC-free product lines, hedging against whatever regulatory outcome arrives.
## The Senate Wild Card
The Senate has not yet taken up its version of the Farm Bill. Hemp industry lobbyists see the Senate markup as the last realistic opportunity to insert CBD-specific protections before the November deadline.
The U.S. Hemp Roundtable and other trade groups have ramped up outreach to Senate Agriculture Committee members, arguing that the current definition would destroy legitimate CBD businesses alongside the intoxicating products it targets.
Their pitch centers on economic data: the USDA’s latest report shows U.S. hemp production value hit $739 million in 2025, up 64% from the prior year. Floral hemp — the segment that includes CBD flower — accounted for nearly 90% of outdoor hemp value.
Eliminating that segment would erase most of the industry’s recent gains while doing nothing to address the gas-station delta-8 products that prompted the crackdown in the first place.
## Reading the Signals
The administration’s position boils down to this: we want to shut down intoxicating hemp products but keep CBD legal. The legislation moving through Congress does not accomplish that distinction. The clock runs out November 12.
Something has to give. Either Congress writes a CBD carve-out into the Senate Farm Bill, or the industry enters November facing a ban that the president himself has called too broad.
For now, CBD businesses should prepare for both outcomes — and watch the Senate calendar closely.
—
*These statements have not been evaluated by the Food and Drug Administration. CBD products are not intended to diagnose, treat, cure, or prevent any disease.*
